We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aptamer Group Plc | APTA | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.625 | 08:00:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.625 | 0.625 | 0.625 | 0.625 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 05/5/2024 02:19 by timbo003 Good evening Multibagger (from Palm Springs, Ca), it is good to have you on board.You may be correct in your analysis bones698, but on the other hand this current dire funding environment will not continue indefinitely. My own view is that we are close to the bottom (if not already off the bottom) of the cycle as far as sentiment towards funding this sort of venture is concerned. As and when sentiment improves, investors will need to change their mindset from expecting a lower price for each successive raise to anticipating upwardly ratcheting prices for each fund raise which will more accurately reflect the (increased) value of the business as projects are progressed and more potential customers are taken on board. Aptamer have sufficient cash until the end of the year, so I suspect they will not need to approach potential funders until Q4, that means there are 4+ months to sign up more deals with the likes of Unilever and the top 15 pharma (precision liver medicine deveopment). It is also worth noting that in the case of Unilever, the project has now moved to the next stage. In my experience (25+ years R&D big pharma/Consumer Healthcare) this step normally represents a significant ratchet up in effort and resources by the customer. Aptamer they will now have an internal champion within Unilever and they have now evidently managed to compete successfully against other (in house and external) Unilever pojects to secure internal resource. One other point to consider, many of Apta's current and prospective customers have very deep pockets and many have an established venture funding arm (including Unilever) so do not rule out one (or more) of them taking a strategic stake in Apta at some stage in the not too distant future. |
Posted at 01/5/2024 07:45 by washingmachine Some big hitter traders / investorsHave been caught out here In deep Turner pope in the mix What could go wrong .. |
Posted at 01/5/2024 07:34 by multibagger Good morning porky9 and all :)Many thanks for a very thorough and considered reply with your perspectives- much appreciated ! I have taken a small position relative to some of the TR1 big hitters we have been hearing of late. I have been doing some digging and asking around: the York scientific community is a small one ! You are right that the previous Board was profligate with Other People's Money. The failing expensive BoD was ejected in Aug 2023 and funding secured at deep discount - the two are interconnected I was told. I was very surprised to learn that neither Prof.Dr. Arron Tolley nor Prof.Dr. David Bunka had a partial cash exit at the time of the IPO as is the norm for founders - they have "lost £ millions" rather than actually made money. They have not enriched themselves, but sadly have been victims of the shenanigans/poor advice of the City folk it would appear (from what I gather). It looks like they went from each controlling 50% of the pre-IPO business to their current equity holdings in low single figures at the current share price - I estimate their personal losses from the current situation to be in the £tens of millions each. Rumour has it that one of the founders challenged the post IPO BoD about profligate spending and was "pushed out". From a scientific and business process, APTA can only initiate work when their customers give them the "target of interest" sample to develop an affinity ligand for. Sometimes the customers themselves are unable to provide the sample it would appear or delays occur. So it would follow that work and contract revenues are lumpy and can convey the impression of a business that is sitting around for orders. Not quite from the stream of news that is being put out and Investor presentations. I am intrigued and my appetite has been whetted - I shall try and learn more in the next few weeks but my gut instinct is that the market is punishing APTA for legacy issues that the current BoD had little to do with. I have a background in science so some of their technical briefings are more understandable to me. A single deal can be £££ transformational and their affinity ligand portfolio/suite seems to be very IP rich and I have been doing Patent searches and love what I see. I am a contrarian and an outlier in many ways and invest accordingly and it has worked for me over the last 3 decades or so...so I have cautiously dipped my toe :) Good luck all ! |
Posted at 30/4/2024 16:16 by multibagger Hi porky9,I am new to this share so don't know much about its past other than it has had a torrid time since listing share price trajectory wise. The technology looks superb and from the Investor Presentations there seems to be 6 or so months worth of cash at a burn of £300k per month if there are no new deals bringing revenue in. At this very low SP, I think that the upside far outweighs the downside risks. For Aptamer Group, a company of less than £3m market cap to be filing for joint Patent Applications with Unilever (personal care division revenues alone circa $23 Billion annually) tells me that there is a lot more than meets the eye. Each to his own and I firmly believe that "Fortuna adjuaces iuvat" ! Good luck all ! |
Posted at 21/3/2024 23:26 by icac the board will keep banging drums to their own beats .unfortunately this stock will lose investors all their money. like I said from day one, if aftamer tech was a game changer , all pharmas from big to small would be all signing contracts.. DYOR |
Posted at 20/3/2024 17:06 by icac they need to start bring cash in otherwise needing investors to bail out again.. from over £1 a share down to this current share price Shocking reward for investors. |
Posted at 20/3/2024 11:45 by icac COULD = when ? = 2025 ? 26? 27?we as investors need answers?? but unfortuneatly those answers is not withing Aptamer hands. we can only speculate operating cost getting lower and lower day by day.. so what's next?? 0.40 , or 0.35?? it's obvious discount raise is happening. sorry, had my moan |
Posted at 28/2/2024 17:20 by npk2 He's not the largest investor, Letsbuy1 is. Oops, they're the same person.What happened to.2p next week5p by Xmas Multiple contracts signed( that was back in December)3% RNS for your holdings.Your that far underwater you'll say anything to get gullible investors in here so you can exit breakeven. |
Posted at 08/2/2024 17:34 by icac most Aim companies always over promise, that's the only way they can suck in investors to invest.. annual profit and loss account do not lie, that's when investors can see the true colour of a company. |
Posted at 22/10/2023 20:40 by secretsqu I feel sorry for the silent investors in this Company that don't feel the need to ramp this to the stars. Those that have done their research and invested accordingly.Why?Well if I was looking to invest in this space, I'd do lots of research. That in itself would throw up numerous red flags that would deem it high risk.Then if I was unfortunate enough to come across the Chuckle Brothers whose only offer of analysis is "Whoosh" "30p" "Get in while you can", I'd run a mile.Not one post is backed up by how and why it's going to get to 2p next week, let alone 30p.The red flags I've seen are in the RNSs. It gets worse when you read their nonsense.These 2 beaut's are probably scaring away, way more investors than they could ever attract.But good luck to the other investors here. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
